1. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17502S1
    Simvastatin-d3 1002347-61-6 98.61%
    Simvastatin-d3 is the deuterium labeled Simvastatin. Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM.
    Simvastatin-d3
  • HY-14838
    Etamicastat 760173-05-5 98%
    Etamicastat (BIA 5-453) is a potent and reversible dopamine-β-hydroxylase (DBH) inhibitor with an IC50 value of 107 nM. Etamicastat can be used in the research of cardiovascular diseases.
    Etamicastat
  • HY-10264A
    Edoxaban tosylate 480449-71-6 99.84%
    Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research.
    Edoxaban tosylate
  • HY-116023
    Moveltipril 85856-54-8 99.89%
    Moveltipril (Moveltipril calcium; MC-838) is a potent angiotensin converting enzyme (ACE) inhibitor.
    Moveltipril
  • HY-117917
    (Rac)-MGV354 1852495-86-3 99.56%
    (Rac)-MGV354 is the racemate of MGV354. MGV354 is a soluble guanylate cyclase (sGC) activator with EC50s of <0.5 nM, and 5 nM in CHO and GTM-3 E cells, respectively.
    (Rac)-MGV354
  • HY-12554B
    Terlipressin acetate 914453-96-6 98.46%
    Terlipressin acetate is a vasopressin analogue with potent vasoactive properties. Terlipressin acetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research.
    Terlipressin acetate
  • HY-131973
    PDE10A-IN-2 hydrochloride 98.43%
    PDE10A-IN-2 hydrochloride is a potent, highly selective and orally active phosphodiesterase 10A (PDE10A) inhibitor with an IC50 of 2.8 nM. PDE10A-IN-2 hydrochloride shows selectivity of >3500-fold against other PDE subtypes. PDE10A-IN-2 hydrochloride can be used for pulmonary arterial hypertension (PAH) research.
    PDE10A-IN-2 hydrochloride
  • HY-139972
    PROTAC(H-PGDS)-7 2761281-50-7 99.42%
    PROTAC(H-PGDS)-7 is a Hematopoietic prostaglandin D synthase (H-PGDS) molecular glue degrader, with a DC50 of 17.3 pM.
    PROTAC(H-PGDS)-7
  • HY-14838A
    Etamicastat hydrochloride 677773-32-9 98.14%
    Etamicastat hydrochloride (BIA 5-453 hydrochloride) is a potent and reversible dopamine-β-hydroxylase (DBH) inhibitor with an IC50 value of 107 nM. Etamicastat can be used in the research of cardiovascular diseases.
    Etamicastat hydrochloride
  • HY-153369
    BAY-747 1609342-18-8 98%
    BAY-747 (BAY 1165747) is an orally active and brain-penetrant stimulator of soluble guanylate cyclase (sGC). BAY-747 reverses L-NAME induced memory impairments and enhances cognition of rats in the object location task (OLT). BAY-747 also decreases blood pressure in both conscious normotensive and spontaneously hypertensive rats (SHR). BAY-747 improves function of the skeletal muscle associated with Duchenne muscular dystrophy (DMD) in mdx/mTRG2 mice model.
    BAY-747
  • HY-160210
    BAY-6096 2313483-41-7 98.07%
    BAY-6096 is a potent, selective, and highly water-soluble adrenergic receptor α2B antagonist with an IC50 of 14 nM. BAY-6096 can effectively reduceα 2B receptor agonist-induced rat vascular contraction.
    BAY-6096
  • HY-B0312S
    Dipyridamole-d20 1189983-52-5 ≥98.0%
    Dipyridamole-d20 is the deuterium labeled Dipyridamole. Dipyridamole is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells.
    Dipyridamole-d20
  • HY-P99177
    Enibarcimab 2305638-98-4 99.68%
    Enibarcimab is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody, could be used for acute heart failure, COVID-19 infections and septic shock research.
    Enibarcimab
  • HY-P99830
    Conbercept 1227158-72-6 98.42%
    Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a vascular endothelial growth factor (VEGF) inhibitor.
    Conbercept
  • HY-108656A
    MRS2365 trisodium ≥99.0%
    MRS2365 trisodium is a potent and selective P2Y1 receptor (EC50=0.4 nM)/[35S]GTPγS binding/β-arrestin 2 recruitment agonist. MRS2365 trisodium relieves mechanical allodynia and increases mechanical sensitivity.
    MRS2365 trisodium
  • HY-111372A
    (Rac)-Finerenone 1050477-27-4 99.66%
    (Rac)-Finerenone ((Rac)-BAY 94-8862) is the racemate of Finerenone. Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold).
    (Rac)-Finerenone
  • HY-113469B
    Cyclic GMP (TBAOH) 99.07%
    Cyclic GMP TBAOH is an endogenous second messenger that triggers interferon production in response to cytoplasmic DNA. Cyclic GMP TBAOH can activate the stimulator of interferon genes (STING), activating the signaling cascade that leads to the production of type I interferons and other immune mediators. Cyclic-GMP-AMP, a conjugate of cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses. Cyclic GMP TBAOH may also activate PDE to degrade cAMP, inhibit myocardial calcium current ICa, and regulate myocardial contractility. The derivative of Cyclic GMP TBAOH, 8-Br-cGMP, has antiplatelet activity, and Cyclic GMP TBAOH can be used in the study of antiviral immunity and cardiovascular diseases.
    Cyclic GMP (TBAOH)
  • HY-B0204S1
    Pimobendan-d3 99.43%
    Pimobendan-d3 (UD-CG115-d3) is deuterium labeled Pimobendan (HY-B0204). Pimobendan (UD-CG115) is a selective inhibitor of PDE3 with IC50 of 0.32 μM.
    Pimobendan-d3
  • HY-14188S
    Amiodarone-d4 hydrochloride 1216715-80-8 99.58%
    Amiodarone-d4 (hydrochloride) is the deuterium labeled Amiodarone hydrochloride. Amiodarone hydrochloride, a benzofuran-based Class III antiarrhythmic agent, inhibits WT outwardIhERG tails with an IC50 of ~45 nM. Amiodarone hydrochloride induces cell proliferation and myofibroblast differentiation via ERK1/2 and p38 MAPK signaling in fibroblasts. Amiodarone hydrochloride can be used in the research of both supraventricular and ventricular arrhythmias.
    Amiodarone-d4 hydrochloride
  • HY-B0193S
    Prazosin-d8 1006717-55-0 ≥98.0%
    Prazosin-d8 is the deuterium labeled Prazosin. Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder.
    Prazosin-d8
Cat. No. Product Name / Synonyms Application Reactivity